Effects of health insurance and race on colorectal cancer treatments and outcomes
- 1 November 2000
- journal article
- research article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 90 (11) , 1746-1754
- https://doi.org/10.2105/ajph.90.11.1746
Abstract
OBJECTIVES: We hypothesized that health insurance payer and race might influence the care and outcomes of patients with colorectal cancer. METHODS: We examined treatments received for all incident cases of colorectal cancer occurring in Florida in 1994 (n = 9551), using state tumor registry data. We also estimated the adjusted risk of death (through 1997), using proportional hazards regression analysis controlling for other predictors of mortality. RESULTS: Treatments received by patients varied considerably according to their insurance payer. Among non-Medicare patients, those in the following groups had higher adjusted risks of death relative to commercial fee-for-service insurance: commercial HMO (risk ratio [RR] = 1.40; 95% confidence interval [CI] = 1.18, 1.67; P = .0001), Medicaid (RR = 1.44; 95% CI = 1.06, 1.97; P = .02), and uninsured (RR = 1.41; 95% CI = 1.12, 1.77; P = .003). Non-Hispanic African Americans had higher mortality rates (RR = 1.18; 95% CI = 1.01, 1.37; P = .04) than non-Hispanic Whites. CONCLUSIONS: Patients with colorectal cancer who were uninsured or insured by Medicaid or commercial HMOs had higher mortality rates than patients with commercial fee-for-service insurance. Mortality was also higher among non-Hispanic African American patients.Keywords
This publication has 70 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- The national cancer data base report on recent hospital cancer program progress toward complete American joint committee on cancer/TNM stagingCancer, 1997
- Perioperative management of colon cancer under Medicare risk programsArchives of internal medicine (1960), 1997
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Best Subsets Logistic RegressionBiometrics, 1989
- Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancerBritish Journal of Surgery, 1987
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987